Linfeng Li

Prof. Dr. Linfeng Li

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
DMDrake M. Mellott
Drake M. Mellott
CTChien-Te Tseng
Chien-Te Tseng
ADAleksandra K Drelich
Aleksandra K Drelich
PFPavla Fajtová
Pavla Fajtová
BCBala C. Chenna
Bala C. Chenna
JMJames H. McKerrow
James H. McKerrow

8 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMing-Zhu Ding
Ming-Zhu Ding
HYHui-Fang Yan
Hui-Fang Yan
LLLinfeng Li
Linfeng Li
FZFang Zhai
Fang Zhai
LSLu-Qing Shang
Lu-Qing Shang
YYYing-Jin Yuan
Ying-Jin Yuan
Identification of efficient key enzymes in biosynthesis pathway and optimization of the fitness between functional modules and chassis are important for improving the production of target compounds. In this study, the taxadiene biosynthesis pathway was firstly constructed in yeast by transforming ts gene and overexpressing erg20 and thmgr. Then, the catalytic capabilities of six different geranylgeranyl diphosphate synthases (GGPPS), the key enzyme in mevalonic acid (MVA) pathway catalyzing famesyl diphosphate (FPP) to geranylgeranyl diphosphate (GGPP), were predicted using enzyme-substrate docking strategy. GGPPSs from Taxus baccata x Taxus cuspidate (GGPPSbc), Erwinia herbicola (GGPPSeh), and S. cerevisiae (GGPPSsc) which ranked 1st, 4th and 6th in docking with FPP were selected for construction. The experimental results were consistent with the computer prediction that the engineered yeast with GGPPSbc exhibited the highest production. In addition, two chassis YSG50 and W303-1A were chosen, and the titer of taxadiene reached 72.8 mg/L in chassis YSG50 with GGPPSbc. Metabolomic study revealed that the contents of tricarboxylic acid cycle (TCA) intermediates and their precursor amino acids in chassis YSG50 was lower than those in W303-1A, indicating less carbon flux was divided into TCA cycle. Furthermore, the levels of TCA intermediates in the taxadiene producing yeasts were lower than those in chassis YSG50. Thus, it may result in more carbon flux in MVA pathway in chassis YSG50, which suggested that YSG50 was more suitable for engineering the taxadiene producing yeast. These results indicated that computer-aided protein modeling directed isoenzyme selection strategy and metabolomic study could guide the rational design of terpenes biosynthetic cells.

26 February 2014 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
PWPeng Wang
Peng Wang
LLLinfeng Li
Linfeng Li
QWQing‐Yin Wang
Qing‐Yin Wang
LSLuqing Shang
Luqing Shang
PSPei-Yong Shi
Pei-Yong Shi
ZYZheng Yin
Zheng Yin

3 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AAAnneliese S. Ashhurst
Anneliese S. Ashhurst
ATArthur H. Tang
Arthur H. Tang
PFPavla Fajtová
Pavla Fajtová
MYMichael C. Yoon
Michael C. Yoon
AAAnupriya Aggarwal
Anupriya Aggarwal
RPRichard J. Payne
Richard J. Payne
Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.

25 November 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYangyang Zhai
Yangyang Zhai
XZXiangshuai Zhao
Xiangshuai Zhao
ZCZhengjie Cui
Zhengjie Cui
MWMan Wang
Man Wang
YWYaxin Wang
Yaxin Wang
ZYZheng Yin
Zheng Yin

11 June 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YMYuying Ma
Yuying Ma
LLLinfeng Li
Linfeng Li
SHShuai He
Shuai He
CSChengyou Shang
Chengyou Shang
YSYang Sun
Yang Sun
LSLuqing Shang
Luqing Shang